50461-56-8

Usage

Uses

Used in Pharmaceutical Industry:
2',3',5',6'-TETRAHYDRO-1'H-2,4'BIPYRIDINYL-4'-OL is used as a therapeutic agent for the treatment of psychiatric disorders such as schizophrenia and depression. Its application is based on its ability to modulate dopamine signaling in the brain, which is implicated in the pathophysiology of these conditions.
Used in Research and Development:
In the field of neuroscience and psychopharmacology, 2',3',5',6'-TETRAHYDRO-1'H-2,4'BIPYRIDINYL-4'-OL is utilized as a research tool to study the role of dopamine D2 receptors in mood regulation and behavior. This helps in understanding the mechanisms underlying psychiatric disorders and aids in the development of new medications for mental health conditions.
Used in Drug Discovery:
2',3',5',6'-TETRAHYDRO-1'H-2,4'BIPYRIDINYL-4'-OL serves as a lead compound in drug discovery for the development of novel medications targeting dopamine D2 receptors. Its structural similarity to dopamine and its agonistic action on these receptors make it a promising candidate for the creation of new therapeutics to address unmet needs in mental health treatment.

Upstream product

• 90606-75-0 4'-Hydroxy-3',4',5',6'-tetrahydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 109-04-6 2-bromo-pyridine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 65869-51-4 1'-benzyl-2',3',5',6'-tetrahydro-1'H-[2,4']bipyridinyl-4'-ol 

Downstream Products

• 1027617-33-9 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-(4'-hydroxy-3',4',5',6'-tetrahydro-2'H-[2,4']bipyridinyl-1'-carbonyl)-1H-pyrazol-4-yl]acetamide 
• 1021202-66-3 3-(1-(4-chloro-2,5-dimethylphenylsulfonyl)piperidin-2-yl)-1-(4-hydroxy-4-(pyridin-2-yl)piperidin-1-yl)propan-1-one 
• 88-99-3 benzene-1,2-dicarboxylic acid 

Relevant academic research and scientific papers

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and/or other disorders and/or disease states.

Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan

A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect. A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both dopamine D 2 and α1-adrenergic receptors. Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]- 1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.

Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity

Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-β mediated diseases and conditions

DIHYDROPYRIMIDINES AND USES THEREOF

This invention is directed to dihydropyrimidines which are selective antagonists for human α 1a receptors. This invention is also related to uses of these compounds for relaxing lower urinary tract tissue, treating benign prostatic hyperplasia and for the treatment of any disease where the antagonism of the α 1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.